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Background: Lung cancer causes 1.4 million deaths worldwide while non-small-cell lung cancer (NSCLC) represents
80-85% of the cases. Cisplatin is a standard chemotherapy against this type of cancer; however, tumor cell
resistance to this drug limits its efficacy. Sea anemones produce compounds with pharmacological activities that
may be useful for augmenting cisplatin efficacy. This study aimed to evaluate the pharmacological activities of
crude venom (CV) from the sea anemone Bunodeopsis globulifera and four derived fractions (F1, F2, F3 and F4)
to test their increase efficiency cisplatin cytotoxicity in human lung adenocarcinoma cells.
Results: Pre-exposure to CV, F1 and F2 fractions increases cisplatin cytotoxicity in human lung adenocarcinoma
cells under specific conditions. Exposure to CV at 50 μgmL-1 induced a reduction of approximately 50% in cell
viability, while a similar cytotoxic effect was observed when cell culture was exposed to F1 at 25 μgmL -1 or F2 at
50 μgmL-1. The cell culture exposure to F1 (10 μgmL-1) fraction combined with cisplatine (25 μM) provoked a
decrease in MTT reduction until 65.57% while F2 (25 μgmL-1) fraction combined with cisplatin (10 μM) provoked a
decrease in MTT reduction of 72.55%.
Conclusions: The F1 fraction had the greatest effect on the lung adenocarcinoma cell line compared with CV and
F2. The combination of antineoplastic drugs and sea anemone toxins might allow a reduction of chemotherapeutic
doses and thus mitigate side effects.
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According to the International Agency for Research on
Cancer (IARC) and World Health Organization, cancer
is a leading cause of death worldwide, accounting for 7.6
million deaths (around 13% of all deaths) in 2008. Lung
cancer causes 1.4 million deaths, followed by sto-
mach (740,000 deaths), liver (700,000 deaths), colorectal
(610,000 deaths) and breast cancer (460,000 deaths).
Around 70% of all cancer deaths occurred in low- and
middle-income countries. Projections to 2030, indicate
about 11 million of cancer deaths worldwide and it is* Correspondence: judithsa@cmarl.unam.mx
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distribution, and reproduction in any mediumexpected that non-small-cell lung cancer (NSCLC) will
represent 80-85% of cases.
NSCLC, which comprises adenocarcinoma, squamous
cell carcinoma and large-cell carcinoma, is an exclusion
diagnosis [1]. Platinum-based chemotherapeutics are the
most common regimens for NSCLC patients but re-
sistance and side effects have limited their efficiency
[2-4]. In this regard, Cis-diammine-dicholoplatinium (II),
known as cisplatin, is an antineoplastic drug widely used
in the treatment of many solid tumors, including lung,
head, neck, ovary, breast, colorectal and cervical cancers
[5,6]. However, the usage of cisplatin in cancer treatment
is limited due to resistance and side effects including
nephrotoxicity [7].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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of new strategies to achieve effectiveness against cancer. In
this sense, the peptides and proteins found in marine
venoms may increase the efficacy of conventional chemo-
therapeutic drugs [8]. In particular, sea anemones produce
peptides and proteins that act as cytolysins which are classi-
fied based on their molecular weight as follows: 5-8 kDa
peptides with antihistamine activity; ~20 kDa pore-forming
proteins; ~30-40 kDa cytolysins with or without phospholi-
pase A2 activity; and a putative protein group ~80 kDa [9].
An essential feature of cytolysins is their ability to
form pores in biological membranes, which lead to
osmotic changes and loss of intracellular metabolites
thereby provoking cell death [10,11]. However, cytolysins
may induce cell damage in both normal and cancer cells
if attached to their membrane. Nevertheless, characte-
ristics of cancer cells are different from normal cells,
including gene profile expression, metabolism and mem-
brane features. In this regard, it has been demonstrated
that cytolysins can induce more damage in cancer cells
due to their differences from normal cells. For this rea-
son, cytolysins have been proposed as an alternative for
cancer therapy [8,12,13].
For example, actinoporins isolated from the tropical
sea anemone Heteractis crispa have shown anticancer
properties through the induction of p53-independent
apoptosis [14]. Bunodeopsis globulifera – found in the
reef lagoon at Puerto Morelos, Quintana Roo, Mexico –
has been reported as producing a highly dangerous sting,
probably due to the toxins it contains [15]. However, the
potential benefits of B. globulifera have been not been doc-
umented. In the present work we hypothesized that toxins
from B. globulifera could increase cytotoxicity induced by
an antineoplastic agent against cancer cells. Specifically,
we are interested in lung cancer cells because the inci-
dence and mortality rates are among the highest in the
world. This study aimed to investigate the ability of crude
venom (CV) and fractions extracted from the sea anemone
B. globulifera to increase the cisplatin-induced cytotoxicity
in lung adenocarcinoma cells. Our results showed for first
time the ability of Bunodeopsis globulifera CV and frac-
tions to increase the cytotoxic effect of a common antineo-
plastic agent used in several types of cancer.
At this point it should be mentioned that toxins from
Bunodeopsis globulifera are cytotoxic like other cnidarian
venoms. However, the purpose of this work is to test
whether the usage of low concentrations of toxins can in-
crease the effect of a low concentration of a common
antineoplasic agent. The general objective of this research
is to design a strategy to decrease the concentrations of
cisplatin and toxins, since this could be helpful in avoiding
the side effects of higher concentrations. For example, cis-
platin is useful to treat lung cancer but provokes nephro-
toxicity as its main side effect. The combination of twodrugs may facilitate the diminution of the side effects asso-
ciated with higher doses.
Methods
Reagents
F-12K Nutrient Mixture medium was purchased from
Gibco Invitrogen (USA). RPMI-1640 medium was obtained
from In Vitro, S.A (Mexico). Fetal bovine serum (FBS) was
from PAA Laboratories (Canada). Cisplatin (cat. n. P4394)
and 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium
bromide (MTT; cat. n. M2128) were purchased from Sigma
Chemical Co. (USA). Lactate dehydrogenase kit (cat. n.
630117) was obtained from Clontech Laboratories, Inc
(USA). Quick Start Bradford Protein Assay Kit (cat. n. 500-
0202) was bought from Bio-Rad Laboratories, Inc (USA).
Sephadex G-50 Medium Gel (cat. n. 17-0043-02) was
obtained from Pharmacia Biotech (Sweden).
Cell cultures
Human A549 non-small-cell lung cancer line, which is an
adenocarcinoma epithelial-derived cell line, was obtained
from the American Type Culture Collection (ATCC, USA).
Cells were cultured in monolayers at 37°C in a humidified
atmosphere of 5% CO2 in F12K medium supplemented
with 10% heat-inactivated FBS.
Isolation and Pre-purification of crude venom
Specimens of Bunodepsis globulifera were collected from
the reef lagoon at Puerto Morelos, Quintana Roo, Mexico,
by scuba diving between February and June, 2009 and
from May to June, 2011. The sea anemones were identified
by Ricardo Gonzalez-Muñoz. The crude venom was
obtained by mincing and homogenizing the whole body of
the sea anemone, and then centrifuging at 3200 g for 15
minutes at 4°C, after which the supernatant was lyophi-
lized. The crude lyophilized venom (4 g) was purified by
Sephadex G-50 M gel filtration column (85 × 5 cm) equili-
brated with 0.3 M acetic acid buffer and eluted with the
same buffer at a flow rate of 2 mL min-1. The four fractions
obtained were concentrated and lyophilized.
Cytotoxicity assays
Lung adenocarcinoma cells (1 × 104 per well/150 μL) were
incubated in 96-well plates and cultured for 24 hours to
allow adherence. After this time, cell culture was exposed
to the following treatments: 1, 10, 25, 50, 75, 100 and
200 μgmL-1; and 10 and 25 μgmL-1 of CV, BgG50F1 and
BgG50F2 fractions of B. globulifera for 24 hours, 37°C and
5% of CO2 atmosphere. After each treatment, the cells were
exposed to cisplatin 10 μM or cisplatin 25 μM for 24 hours.
Cell viability assay and cytotoxicity
Cell viability was measured by the reduction of MTT to
formazan blue. Cell culture was incubated with 0.5 mg/mL
Figure 1 Gel filtration chromatography Sephadex G-50 M of CV (4 g) from B. globulifera. The column was equilibrated and eluted with
0.3 M acetic acid buffer at a flow rate of 2 mL min-1 to obtain the fractions F1, F2, F3 and F4.
Table 1 Protein quantification of CV and fractions isolated
from B. globulifera at 1 mgmL-1 using the Bradford method
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medium was removed and the formazan blue crystals were
dissolved in isopropyl alcohol for measuring the optical
density at 540 nm [16].
The cytotoxicity was measured using a lactate de-
hydrogenase (LDH) cytotoxicity detection kit according
to the manufacturer’s protocol. Briefly, supernatants
from cell treatments were collected and diluted 1:3 with
PBS. After that, supernatant dilution was mixed 1:1 with
dye solution and incubated at 37°C for 30 minutes under
agitation; and absorbance was measured at 540 nm.
Quantification of protein
The protein content was measured by the Bradford assay
[17] using bovine gamma globulin (BGG) as standard.
SDS-PAGE electrophoresis
The obtained fractions were assessed by SDS-PAGE
according to Laemmli [18] using a 12% polyacrylamide
gel for the molecular weight determination.
Statistical analysis
Data were expressed by mean ± SD, followed by one-way
analysis of variance (ANOVA) with Bonferroni’s multiple
comparison tests, performed using GraphPad Prism for
Windows (GraphPad Software, USA). p < 0.001 was con-
sidered to be statistically significant.
Results
Pre-purification of crude venom from B. Globulifera
Crude venom (CV) of B. globulifera was obtained by
mincing and homogenizing the whole body of the sea anem-
one. It was centrifuged at 3200 g for 15 minutes at 4°C, and
the supernatant was lyophilized. Crude venom was purifiedby gel filtration in a Sephadex G-50 M column and eluted
with 0.3 M acetic acid buffer at a flow rate of 2 mL min-1.
Four fractions – F1, F2, F3 and F4 – were obtained. There-
after, fractions were vacuum-concentrated and lyophilized
(Figure 1). Table 1 shows the protein content of CV, F1, F2,
F3 and F4 quantified by the Bradford method [17].
The cytotoxic effects of CV as well as the F1, F2, F3 and
F4 fractions were tested on a human lung adenocarcinoma
cell line using an MTTassay. The exposure to 1 μgmL-1 or
10 μgmL-1 to CV did not induce changes in MTT reduc-
tion. However, CV at 25 μgmL-1, 50 μgmL-1, 75 μgmL-1,
100 μgmL-1 and 200 μgmL-1 decreased cell viability by the
following percentages: 33.37, 55.46, 65.8, 68.36 and 70.44,
respectively (Figure 2A). The exposure to F1 at 1 μgmL-1
or 10 μgmL-1 did not show a cytotoxic effect; however,
25 μgmL-1, 50 μgmL-1, 75 μgmL-1, 100 μgmL-1 and
200 μgmL-1 induced respective decreases in cell viability of
47.11%, 60.21%, 65.27%, 70.87% and 72.35% (Figure 2B).
The exposure to F2 at 1 μgmL-1 or 10 μgmL-1 did not pro-
duce any change in MTT reduction, but 50 μgmL-1,
75 μgmL-1, 100 μgmL-1 and 200 μgmL-1 induced cell-
viability diminutions of 36.49%, 55.83%, 69%, 71.27% and
77.13%, respectively (Figure 2C). The F3 and F4 did not
Figure 2 Cytotoxicity induced by CV and the fractions F1 and F2 from B. globulifera at the concentrations 1, 10, 25, 50, 75, 100 and
200 μgmL-1 on lung adenocarcinoma cell culture. Effect of: (A) CV, (B) F1 fraction, (C) F2 fraction. Graphs show the percentage of MTT
reduction. Data are expressed as the mean ± SD of four independent experiments. Significance was defined as *** p < 0.001 (ANOVA, Bonferroni’s
post test) in comparison with the untreated control values (100%).
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Figure 3 Concentration-response effect of cisplatin on lung adenocarcinoma cell culture: cell viability was measured by MTT assay.
Data are expressed as the mean ± SD of four independent experiments. *p < 0.01 vs. control, one-way analysis of variance, with Bonferroni’s test.
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considered for further experiments in the present work.
Inhibitory concentration (IC50) values for cisplatin
The cisplatin concentration that inhibited cell growth by
50% (IC50) was determined in a human lung adenocarci-
noma cell line. A cisplatin concentration between 1 and
250 μM was used in cell culture for 24 hours in three inde-
pendent experiments. After treatment, cytotoxicity was
tested by MTT reduction and the IC50 found to be 50 μM
(Figure 3). However, concentrations below IC50 were used
to test whether CV and its fractions could enhance the cis-
platin cytotoxicity. Human lung adenocarcinoma cells ex-
posed to cisplatin at 1 and 10 μM remained without
changes in MTT reduction; however, cisplatin concentra-
tions of 25, 50, 100 and 250 μM induced respective cell-
viability decreases of 23.64%, 53.59%, 58.98% and 64.64%
(Figure 3). We selected cisplatin concentrations of 10 μM
and 25 μM, which are below the IC50.
CV, F1 and F2 enhanced cisplatin-induced cytotoxicity
Lung adenocarcinoma cells were pre-exposed to CV, F1
or F2 at 10 μgmL-1 or 25 μgmL-1 for 24 hours. After this
time, the medium was removed and cell culture was
washed and exposed to cisplatin at 10 μM or 25 μM.
The abovementioned strategy was executed in order to
increase cisplatin cytotoxicity by pretreatment with CV,
F1 or F2 at low concentration.
The pretreatment with CV at 10 μgmL-1 plus cisplatin at
25 μM yielded a 26.47% decrease in cell viability; the pre-
treatment with 25 μgmL-1 CV plus 10 μM cisplatin aug-
mented the cell-viability decrease to 30.22%. But the
maximum effect was produced by 25 μgmL-1 CV plus
25 μM cisplatin (Figure 4A). However, the pre-exposure to
CV did not increase the cisplatin-induced cytotoxicity
(Figure 4A).The pre-exposure to F1 at 10 μgmL-1 caused a decrease
in MTT reduction induced by 10 μM and 25 μM of cis-
platin to 66.39% and 68.4%, respectively (Figure 4B). The
pre-exposure to 25 μgmL-1 F1 had similar effect; it reduced
cell viability down to 72.55% after exposure to 25 μM cis-
platin (Figure 4B). The 10 μgmL-1 F2 increased the cyto-
toxicity induced by 10 μM cisplatin to 51.56% (Figure 4C).
Then, while evaluating the LDH release into the cell cul-
ture medium as a loss of membrane integrity, we observed
that 10 μgmL-1 CV plus 25 μM cisplatin and 25 μgmL-1
CV plus 25 μM cisplatin induced significant increases
of 2.665- and 2.799-fold in LDH release, respectively
(Figure 5A). The pre-exposure to F1 at 25 μgmL-1 plus
cisplatin at 25 μM produced a significant 2.858 fold in-
crease in LDH release (Figure 5B). Pre-exposure to 10 and
25 μgmL-1 F2 showed no statistical increase in cytotoxicity
induced by 25 and 10 μM cisplatin (Figure 5C).
Discussion
The present work showed that CV of B. globulifera and F1
and F2 obtained from pre-purification by Sephadex G-50
M gel filtration chromatography induced cytotoxicity in a
human lung adenocarcinoma cell line. Exposure to CV at
50 μgmL-1 induced a reduction of approximately 50% in
cell viability, while a similar cytotoxic effect was observed
when cell culture was exposed to F1 at 25 μgmL-1 or F2 at
50 μgmL-1.
This cytotoxic effect has been also presented by other
sea anemones, such as crude venoms of Heteractis
magnifica, Stichodactyla haddoni and Parachondylactis
sinensis on mouse fibroblast cell line L929 and leukemia
cell line P388. In those studies, the decrease in cell via-
bility was concentration-dependent [19]. EqTX-II cytoly-
sin toxin from the sea anemone Actinia equina also
induces a decrease in the viability of V-79-379 A cells
(diploid lung fibroblast from Chinese Hamster) in a
Figure 4 Cytotoxic effect induced by CV, F1 and F2 fraction from B. globulifera on adenocarcinoma lung cell culture. (A) CV, (B) F1
fraction plus cisplatin, (C) F2 fraction plus cisplatin. Graphs show the percentage of MTT reduction and data are expressed as the mean ± SD
of four independent experiments. ***p < 0.001 vs. control, $p < 0.001 vs. Cis 10, &p < 0.001 vs. Cis 25, #p < 0.001 vs. CV 10 or F1-10 or F2-10,
□ p < 0.001 vs. CV 25 or F1-25 or F2-25 (One-way analysis of variance plus Bonferroni’s test). Gray bars show the ability of (B) F1 and (C) F2 to
augment the cisplatin decrease in MTT reduction.
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Figure 5 Cytotoxic effect induced by CV, F1 and F2 fraction from B. globulifera on adenocarcinoma lung cell culture: (A) CV, (B) F1
fraction plus cisplatin, (C) F2 fraction plus cisplatin. Graphs show the percentage of LDH release, with data expressed as the mean ± SD
of four independent experiments. ***p < 0.001 vs. control, $p < 0.001 vs. Cis 10, &p < 0.001 vs. Cis 25, #p < 0.001 vs. CV 10 or F1-10 or F2-10,
□ p < 0.001 vs. CV 25 or F1-25 or F2-25 (one-way ANOVA, Bonferroni’s post test) (a) CV plus cis, (b) F1 plus cis, (c) F2 plus Cis. Gray bars showed
the ability of (B) F1 and (C) F2 to increase the cisplatin-induced LDH release.
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from the sea anemone Heteractis crispa reduced cell via-
bility of JB6 P+ Cl41 cells, Hela, THP-1, MDA-MB-231
and snu-c4 human tumor cell lines [14].
These results have shown that sea anemone toxins and
some proteins derived from them exert cytotoxic activity
on a non-small lung cancer cell lines, although the cyto-
toxic mechanisms induced by the sea anemone toxins have
been sparsely investigated. In this regard, Soletti et al. [8]
showed that the cytolysins EqTx-II and Bc2 from sea anem-
ones potentiated the cytotoxicity induced by low-dose con-
centrations of the chemotherapeutic drugs against human
glioblastoma cells through necrosis-like cell death [8].
In the present work, it has been observed that CV, F1
and F2 fractions from B. globulifera increase the cyto-
toxic effect induced by cisplatin under specific condi-
tions. The exposure to F1 at 10 μgmL-1 induced a
decrease of 40.02% in MTT reduction versus 11.12% by
cisplatin. However, the pre-exposure to F1 (10 μgmL-1)
provoked a decrease in MTT reduction of 66.30%
(Figure 4B). The combination of F1 (10 μgmL-1) and
25 μM cisplatin decreased the MTT reduction to
67.57%, which may indicate the absence of a difference
between 10 μM and 25 μM cisplatin (Figure 4B). The
exposure to 25 μgmL-1 F1 induced a decrease of 53.42%
in MTT reduction but in combination with 25 μM
cisplatin, which by itself induced a decrease of 25.55%
in MTT, there was a decrease of 72.55% (Figure 4B).
A similar effect was observed when lung adenocarci-
noma cell line was exposed to 25 μgmL-1 F2 followed by
10 μM cisplatin, which induced a decrease of 51.56% in
MTT reduction, while 25 μgmL-1 F2 induced only a de-
crease of 33.48% and 10 μM cisplatin a decrease of
11.12% in MTT reduction (Figure 4C).
LDH activity was measured in a cell culture medium,
since this enzyme is released under conditions of cell
damage, wherein we observed that 10 μgmL-1 CV in-
duced an increase of 17.5% of activity versus 98% by
25 μM cisplatin; the combination induced 166.59% of in-
crease (Figure 5A). The augmentation of LDH activity
was 45% after exposure solely to CV at 25 μgmL-1, but
rose to 1423.3% when this CV was combined with
25 μM cisplatin (Figure 5A). This finding may signify the
absence of a real difference between 10 and 25 μgmL-1
CV. Similarly, the 71.6% increase in LDH activity pro-
duced by treating cell culture with only F1 at 25 μgmL-1
rose to 185.8% when the fraction was combined with
25 μM cisplatin (Figure 5B).
Based on the results of the present work, we suggest
not only that CV, F1 and F2 may present different mech-
anisms of cell damage in lung adenocarcinoma cells, but
also that CV may augment cell damage by compromi-
sing the membrane, given the evident changes in LDH
release (Figure 5A), and F2 fraction, which could causehigher mitochondrial damage, since MTT reduction is
related to mitochondrial activity (Figure 5C). However,
F1 fraction may produce greater mitochondrial alter-
ations and membrane damage (Figures 4B and 5B) than
CV and F2 fraction.
Interestingly, this study proposes the usage of cisplatin
at a dose below IC50, which in turn might represent
fewer side effects. It is also interesting that cisplatin
causes hardly any mitochondrial damage below 25 μM;
however, the F1 and F2 fractions caused more damage,
as measured by MTT reduction, than cisplatin alone
while their combination seems to produce an additive ef-
fect (Figure 4B and C). It is also compelling that the
combination of CV and F1 fraction with cisplatin ap-
pears to have synergistic effect, specifically in LDH re-
lease (Figure 5A and B).
Based on the data of the present work, we suggest that
more studies are needed to investigate the cytotoxicity
mechanism of CV, F1 and F2, which could help to de-
sign a combinatory treatment to increase the effects of
antineoplasic agents, including cisplatin. We also suggest
that these compounds may execute their toxicity though
a different cellular mechanism that includes mitochon-
drial damage and alterations of the cell membrane.Conclusions
We observed that CV of B. globulifera and its F1 and F2
fractions obtained by Sephadex G-50 M gel filtration have a
cytotoxic effect on the A549 lung cancer cell line. The F1
fraction had the greatest effect compared with CV and F2.
The combination of antineoplastic drugs and sea anemone
toxins might allow a reduction of chemotherapeutic doses
and thus mitigate side effects. It will be necessary to evalu-
ate not only the damage and action mechanisms in lung
adenocarcinoma cells, but also whether these compounds
are cytotoxic to different types of lung cancer cells and
other cancer cell lines, including breast, cervix and colon
cancers, each of which has a high incidence and prevalence.
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